Avenue Therapeutics, Inc.

BST:49Y0 Stock Report

Market Cap: €3.4m

Avenue Therapeutics Valuation

Is 49Y0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 49Y0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 49Y0 (€6) is trading below our estimate of fair value (€111.35)

Significantly Below Fair Value: 49Y0 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 49Y0?

Other financial metrics that can be useful for relative valuation.

49Y0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does 49Y0's PB Ratio compare to its peers?

The above table shows the PB ratio for 49Y0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.2x
B8FK Biofrontera
1xn/a€17.1m
SBX SynBiotic
1.9x107.0%€31.9m
HIGH Cantourage Group
1.3x110.6%€58.1m
0RX Redx Pharma
16.6x-22.3%€65.0m
49Y0 Avenue Therapeutics
2.3x7.9%€3.7m

Price-To-Book vs Peers: 49Y0 is expensive based on its Price-To-Book Ratio (2.3x) compared to the peer average (1.6x).


Price to Earnings Ratio vs Industry

How does 49Y0's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No more companies

Price-To-Book vs Industry: 49Y0 is good value based on its Price-To-Book Ratio (2.3x) compared to the European Pharmaceuticals industry average (2.3x).


Price to Book Ratio vs Fair Ratio

What is 49Y0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

49Y0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 49Y0's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 49Y0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€1,140.93
0%
95.4%€2,229.61€52.26n/a2
Oct ’25n/a
€1,140.93
0%
95.4%€2,229.61€52.26n/a2
Sep ’25n/a
€1,140.93
0%
95.4%€2,229.61€52.26n/a2
Aug ’25€3.36
€1,140.93
+33,856.3%
95.4%€2,229.61€52.26n/a2
Jul ’25€3.32
€1,140.93
+34,265.4%
95.4%€2,229.61€52.26n/a2
Jun ’25n/a
€1,140.93
0%
95.4%€2,229.61€52.26n/a2
May ’25€5.28
€1,140.93
+21,492.2%
95.4%€2,229.61€52.26n/a2
Apr ’25n/a
€1,140.93
0%
95.4%€2,229.61€52.26n/a2
Mar ’25n/a
€1,140.93
0%
95.4%€2,229.61€52.26n/a2
Feb ’25n/a
€1,140.93
0%
95.4%€2,229.61€52.26n/a2
Jan ’25n/a
€1,140.93
0%
95.4%€2,229.61€52.26n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies